GV participated in tech apprenticeship platform Multiverse’s $220m series D round while Amgen, UCB, UPMC and Takeda helped genetics disease drug developer Code Biotherapeutics raise $75m.

Funding US-headquartered, technology-focused apprenticeship provider Multiverse has received $220m in series D funding from investors including internet technology group Alphabet’s GV unit. StepStone Group, Lightspeed Venture Partners and General Catalyst co-led the round, which also featured Founders Circle Capital, Audacious Ventures, Bond, D1 Capital Partners and Index Ventures. The round valued the company at $1.7bn…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.